Weiss Lawrence T 4
4 · ANGIODYNAMICS INC · Filed Jul 22, 2026
Research Summary
AI-generated summary of this filing
AngioDynamics (ANGO) SVP Lawrence T. Weiss Receives Equity Award
What Happened
Lawrence T. Weiss, Senior Vice President and Chief Legal Officer of AngioDynamics, received equity awards on July 15, 2026: 21,288 restricted stock units (RSUs) and 21,288 performance rights. Both awards were granted at $0 per share (standard for equity awards) and reported on a Form 4 filed July 22, 2026. These are grants (not open-market purchases or sales) and represent compensation rather than a cash transaction.
Key Details
- Transaction date: July 15, 2026; Form 4 filed July 22, 2026 (appears outside the typical 2-business-day filing window).
- Award types and amounts: 21,288 RSUs and 21,288 performance rights (both reported as acquisitions, code “A”). Grant price reported $0.
- Vesting for RSUs (F1): RSUs vest in four equal annual installments beginning July 15, 2027 (25% vests each July 15 in 2027, 2028, 2029, 2030).
- Performance rights (F2): Each right converts to one share if earned. Payout ranges from 0%–200% of target based on total shareholder return (TSR) vs. peers over a three-year period, with a possible ±20% adjustment on the calculated achievement — for a total potential payout up to 240% of target (i.e., up to roughly 51,091 shares at maximum). Any unearned performance rights are forfeited.
- Shares owned after transaction: not specified in the provided excerpt.
- Filing timeliness: filing date is July 22 for a July 15 grant — this appears late relative to the usual 2-business-day Form 4 deadline.
Context
These awards are part of executive compensation and common practice to align management incentives with shareholder performance. RSUs provide time-based retention, while the performance rights tie payout to relative TSR over a multi-year period; neither represents an immediate cash investment or sale by the insider.
Insider Transaction Report
- Award
Common Stock
[F1]2026-07-15+21,288→ 112,618 total - Award
Performance Right
[F2]2026-07-15+21,288→ 21,288 total→ Common Stock (21,288 underlying)
Footnotes (2)
- [F1]The acquisition of 21,288 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 21,288 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 15, 2027, such that 25% of the restricted stock units will vest on each of July 15, 2027, 2028, 2029 and 2030.
- [F2]Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.